Pluri Inc. (PLUR)
4.28
-0.02 (-0.47%)
At close: Apr 02, 2025, 3:43 PM
4.20
-1.87%
After-hours: Apr 02, 2025, 04:05 PM EDT
-0.47% (1D)
| Bid | 3.9 |
| Market Cap | 30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -1.16 |
| Forward PE | -13.33 |
| Analyst | n/a |
| Ask | 4.4 |
| Volume | 3,591 |
| Avg. Volume (20D) | 10,146 |
| Open | 4.21 |
| Previous Close | 4.30 |
| Day's Range | 4.18 - 4.29 |
| 52-Week Range | 4.07 - 6.60 |
| Beta | 1.76 |
About PLUR
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respir...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2003
Employees 106
Stock Exchange NASDAQ
Ticker Symbol PLUR
Website https://pluri-biotech.com/
3 months ago
+4.76%
Pluri shares are trading higher after the company ...
Unlock content with
Pro Subscription
4 months ago
+11.84%
Brainstorm Cell Therapeutics and Pluri shares are trading higher after the companies entered into a memorandum of understanding to manufacture NurOwn for a Phase 3b trial in amyotrophic lateral sclerosis.
